CORT

Over the last 7 days, the United States market has risen by 1.1%, contributing to an impressive 27% climb over the past year, with earnings forecasted to grow by 17% annually. In this thriving environment, companies that exhibit high growth potential and significant insider ownership can be particularly appealing, as they often indicate strong confidence from those closest to the business. Click here to see the full list of 181 stocks from our Fast Growing US Companies With High Insider Ownership screener. Let's take a closer look at a couple of our picks from the screened companies. Simply Wall St Growth Rating: ★★★★☆☆ Overview: Evolus, Inc. is a performance beauty company that provides products in the cash-pay aesthetic market across the United States, Canada, Europe, and Australia with a market cap of $442.54 million. Operations: The company's revenue segment focuses on delivering medical aesthetic products to the cash-pay aesthetic market, generating $301.79 million. Insider Ownership: 11.1% Earnings Growth Forecast: 66.7% p.a. Evolus, Inc. is poised for significant growth with its forecasted profitability within three years and revenue growth expected to outpace the broader US market at 14.4% annually. Recent earnings show a narrowing net loss, and the company anticipates annual revenues between US$327 million and US$337 million for 2026. The upcoming European launch of Estyme marks an international expansion in dermal fillers, potentially enhancing revenue streams despite historically volatile share prices and negative shareholders' equity concerns. Click here and access our complete growth analysis report to understand the dynamics of Evolus. Our expertly prepared valuation report Evolus implies its share price may be lower than expected. Simply Wall St Growth Rating: ★★★★★★ Overview: Upstart Holdings, Inc. operates a cloud-based AI lending platform in the United States and has a market cap of approximately $2.58 billion. Operations: The company's revenue is primarily derived from its personal lending segment, which generated $1.01 billion. Insider Ownership: 12.8% Earnings Growth Forecast: 58.5% p.a. Upstart Holdings is positioned for robust growth, with earnings projected to rise significantly at 58.5% annually, outpacing the US market. Despite a recent net loss of US$6.65 million in Q1 2026, insider activity indicates more buying than selling over...

In the last week, the United States market has stayed flat, yet it has seen a remarkable 25% increase over the past year with earnings forecasted to grow by 17% annually. In this thriving environment, growth companies with high insider ownership can be particularly appealing as they often indicate strong confidence from those closest to the business in its potential for continued success. Click here to see the full list of 187 stocks from our Fast Growing US Companies With High Insider Ownership screener. Below we spotlight a couple of our favorites from our exclusive screener. Simply Wall St Growth Rating: ★★★★★☆ Overview: Aeluma, Inc. develops optoelectronic and electronic devices for sensing, communication, and computing applications in the United States with a market cap of $488.06 million. Operations: The company's revenue is primarily derived from its Semiconductor Equipment and Services segment, which generated $5.23 million. Insider Ownership: 25.8% Earnings Growth Forecast: 68.6% p.a. Aeluma is positioned for significant growth with forecasted revenue expansion of 77% annually, outpacing the US market. Despite a volatile share price and recent net losses, its strategic focus on high-growth sectors like AI infrastructure and quantum technologies is bolstered by substantial U.S. government contracts exceeding US$4 million. The company's innovative quantum dot laser platform, supported by NASA awards, enhances its competitive edge in photonics integration. However, low projected return on equity remains a concern. Click to explore a detailed breakdown of our findings in Aeluma's earnings growth report. Our valuation report here indicates Aeluma may be overvalued. Simply Wall St Growth Rating: ★★★★☆☆ Overview: STAAR Surgical Company designs, develops, manufactures, and sells phakic implantable lenses and accessory delivery systems for the eye, with a market cap of approximately $1.40 billion. Operations: The company's revenue is primarily generated from its ophthalmic surgical products, totaling $239.44 million. Insider Ownership: 26.2% Earnings Growth Forecast: 71.6% p.a. STAAR Surgical's growth potential is underscored by its forecasted revenue increase of 11.8% annually, slightly above the US market average. Recent earnings showed significant improvement with sales reaching US$93.52 million, a substantial rise from the previous year, and a shift to n...

Image source: The Motley Fool. Thursday, July 31, 2025 at 5 p.m. ET Chief Executive Officer — Joseph K. Belanoff, M.D. President, Endocrinology — Sean Maduck Chief Business Officer — Gary Charles Robb Chief Development Officer — William Guyer President, Oncology — Roberto W. Vieira Chief Financial Officer — Atabak Mokari Need a quote from a Motley Fool analyst? Email [email protected] Our revenue in the second quarter of 2025 was $194.4 million, compared to $163.8 million in the prior year period. We have modified our 2025 revenue guidance to $850 million to $900 million. Net income was $35.1 million compared to $35.5 million in the second quarter of last year. Our cash and investments at June 30 were $515 million. Balance reflects our acquisition of $115 million of our common stock in the second quarter, pursuant to our stock repurchase program, the net exercise of stock options by Corcept employees and the net vesting of restricted stock grants. I'll now turn the call over to Sean Maduck, President of our Endocrinology division. Sean? Sean Maduck: Thank you, Atabak. The endocrinology division had an excellent second quarter. For the sixth quarter in a row, we added a record number of new prescribers and new prescriptions, and there are a record number of patients on therapy. We shipped more tablets to patients than ever before, 49% more than the second quarter last year. Our financial results don't fully reflect the surge in demand. While our quarterly revenue growth was substantial, a $37 million increase over the first quarter, it should have been more. I discussed on the last call the insufficient capacity of our pharmacy vendor. Its capacity has increased in the second quarter but not as much as we expected and not enough to keep pace with our growth. Capacity will increase further in the second half of the year. We dispensed another record number of tablets in July with more increases to follow. We are also bringing online a second pharmacy. You will see the financial impact of this addition in the fourth quarter. Increased pharmacy capacity is important because I'm certain our growth is poised to accelerate. For many years, physicians only screened and treated the most physically obvious cases of hypercortisolism. In the last 15 years, many studies have been published supporting the identification and the treatment across a much broader spectrum of disease...

Image source: The Motley Fool. Thursday, April 30, 2026 at 5 p.m. ET Chief Executive Officer — Joseph K. Belanoff Chief Financial Officer — Atabak Mokari President, Endocrinology — Sean Maduck President, Oncology — Roberto Vieira Chief Development Officer — William Guyer Need a quote from a Motley Fool analyst? Email [email protected] Our revenue in the first quarter of 2026 was $164.9 million compared to $157.2 million in the prior year period. We have increased our 2026 revenue guidance to $950 million to $1.05 billion. Net loss was $31.8 million in the first quarter of 2026 compared to net income of $20.5 million in the first quarter of last year. Our cash and investments at March 31 were $515 million. I will now turn the call over to Sean Maduck, President of our endocrinology division. Sean? Sean Maduck: Thanks, Atabak. Demand for our medications continues to increase. We ended the first quarter with a record number of new prescriptions written from a record number of prescribers, which translated to an all-time high for the number of patients receiving our medications. Importantly, we set a record for new patient starts in March and again in April. These figures are outstanding and give me great confidence in the current and future health of our hypercortisolism business. The full impact is not reflected in our revenue for 3 reasons. First, revenue often dips in the first quarter as it does for many rare disease medications because insurance companies impose onerous reauthorization procedures at the start of each year that interrupt patient coverage for a month or 2. We provide patients with free drug to bridge the gap, but our revenue suffers. Second, new patients, whom we are adding at a rapid clip, provide much less revenue when they start treatment than they will later after payer coverage has been secured and they have titrated to their optimum dose. The full revenue impact of patients added this quarter will grow substantially over the next few quarters. Finally, our specialty pharmacy vendor has done an excellent job onboarding the thousands of patients transferred from our former vendor and getting them the medicine they've been prescribed. They have also excelled at servicing new prescriptions written for our medications, the new patient starts I just described. The task that remains is grinding through the insurance prior authorization backlog that...

Image source: The Motley Fool. Tuesday, February 24, 2026 at 5 p.m. ET Chief Executive Officer — Joseph K. Belanoff Chief Business Officer — Gary Robb Chief Financial Officer — Atabak Mokari President, Endocrinology Division — Sean Maduck Chief Development Officer — William Guyer President, Oncology Division — Roberto Vieira Atabak Mokari: Hello, everyone. Good afternoon, and thank you for joining us. Today, we issued a press release announcing our financial results for the full year and providing a corporate update. A copy is available at corcept.com. Our complete financial results will be available when we file our Form 10-K with the SEC. Today's call is being recorded. A replay will be available at the Investors Past Events tab of our website. Statements during this call, other than statements of historical fact are forward-looking statements based on our plans and expectations that are subject to risks and uncertainties, which might cause actual results to be materially different from those such statements expressed or implied. The risk and uncertainties that may affect our forward-looking statements are described in our annual report on Form 10-K and our quarterly reports on Form 10-Q, which are available on the SEC's website. Please refer to those documents for more information. We disclaim any intention or duty to update forward-looking statements. Our 2025 revenue was $761 million compared to $675 million in the prior year. We expect our revenue growth to continue and are providing full year 2026 revenue guidance of $900 million to $1 billion. Net income was $99.7 million for the full year 2025 compared to $141.2 million in the prior year. Cash and investments at December 31, 2025, were $532 million, which reflects our acquisition in 2025 of $245 million worth of our common stock pursuant to our stock repurchase program as well as shares acquired upon the exercise of Corcept stock options and the vesting of restricted stock rates. I will now turn the call over to Charlie Robb, our Chief Business Officer. Charlie? Gary Robb: Thanks, Atabak. As many of you know, last Thursday, the Federal Circuit Court of Appeals ruled against us in our lawsuit to stop Teva Pharmaceuticals from marketing a generic version of Korlym in violation of our patents. We believe the court made a mistake. Patents we have asserted as included in Korlym's label and Teva's copy of...

Image source: The Motley Fool. Monday, May 5, 2025 at 5 p.m. ET Chief Executive Officer — Joseph K. Belanoff President, Endocrinology — Sean Maduck President, Oncology — Roberto Vieira Chief Business Officer — Charles Robb Chief Development Officer — William Guyer Our revenue in the first quarter of 2025 was $157.2 million, compared to $146.8 million in the first quarter of last year. We are reiterating our 2025 revenue guidance of $900 million to $950 million. Net income was $20.5 million in the first quarter of 2025, compared to $27.8 million in the first quarter of last year. Our cash and investments at March 31st were $570.8 million. We acquired $43 million of our common stock in the first quarter of 2025 pursuant to our stock repurchase program, the net exercise of stock options by Corcept employees and the net vesting of restricted stock. I will now turn the call over to Sean Maduck, President of our Endocrinology division. Sean? Sean Maduck: Thank you, Atabak. We are on the cusp of a new diagnosis and treatment paradigm for patients with hypercortisolism. For many years, most physicians reserved both screening and treatment for the most physically obvious cases of hypercortisolism. Over the last 15 years, published data supported the identification and the treatment across a broader spectrum of disease. Screening for hypercortisolism has increased and it is driving rapid patient growth in our business. I’m certain that this increase in screening is just beginning. I’ve never been more confident in both our current and future growth prospects, and most important, our potential to help many, many patients for years to come. We now know that patients with hypercortisolism exist in every medical practice. More and more physicians are starting to recognize that, too. To put this in perspective, our new prescriber base has grown at a record rate for five straight quarters, and the number of Korlym prescriptions in the first quarter of this year was almost double what we saw in the same period last year. Both our prescriber base and our patient base are growing rapidly, and we expect growth to accelerate. In 2023 and 2024, we amplified our efforts to educate physicians about hypercortisolism and Korlym. We also increased the size of our sales force and we will continue to grow that team to reach and serve all our potential customers. We currently have 125 cl...

Revenue of $164.9 million, compared to $157.2 million in first quarter 2025 Increase in 2026 revenue guidance to $950 – $1,050 million Net loss of $31.8 million, compared to net income of $20.5 million in first quarter 2025 Cash and investments of $515.4 million at March 31, 2026 Lifyorli™ (relacorilant) approved by FDA in March 2026 for the treatment of patients with platinum-resistant ovarian cancer REDWOOD CITY, Calif., April 30, 2026--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today reported its results for the quarter ended March 31, 2026. Financial Results Corcept’s first quarter 2026 revenue was $164.9 million, compared to $157.2 million in the first quarter of 2025. First quarter 2026 operating expenses were $214.5 million, compared to $153.8 million in the same period last year, due to increased spending to prepare for the launch of Lifyorli to treat patients with platinum-resistant ovarian cancer and to invest in growth initiatives in our Cushing’s syndrome business. Net loss per common share (diluted) was $0.30 in the first quarter of 2026, compared to net income per common share (diluted) of $0.17 in the first quarter of 2025. Corcept expects to return to profitability in the second quarter of 2026. Cash and investments were $515.4 million at March 31, 2026, compared to $532.4 million at December 31, 2025. "This quarter’s results include a significant milestone: With the FDA’s approval of Lifyorli (relacorilant) to treat women with platinum-resistant ovarian cancer more than three months before its PDUFA date, this is the last quarter for which our financial results will reflect the sales of just one medication. In April, Lifyorli, in combination with nab-paclitaxel, was added to NCCN Guidelines® as a preferred regimen and uptake has been vigorous. In February, our Cushing’s syndrome business completed its transition to our new pharmacy vendor, which is successfully fulfilling the increasing demand for Korlym and our authorized generic. March and April marked all-time highs in the number of patients starting treatment. We have increased our 2026 revenue guidance to $950 – $1,050 million," said Joseph K. Belanoff, M...

Corcept Therapeutics CORT incurred a first-quarter 2026 loss of 30 cents per share, in line with the Zacks Consensus Estimate. In the year-ago quarter, the company had reported earnings of 17 cents per share. First-quarter revenues rose 4.9% year over year to $164.9 million but missed the Zacks Consensus Estimate of $172 million. The top line consisted solely of product sales from Cushing’s syndrome drug Korlym. Revenues from Korlym, however, missed our model estimate of $169.3 million. Year to date, shares of Corcept have rallied 33.7% against the industry’s decline of 2.5%. Image Source: Zacks Investment Research Corcept’s first-quarter 2026 sales were driven by its established Cushing’s syndrome franchise, with management highlighting rising demand for Korlym. The company said March and April marked all-time highs in the number of patients starting treatment, following completion of a transition to a new pharmacy vendor earlier in the quarter. Importantly, management framed the period as a turning point for the business model. With the recent FDA approval of Lifyorli (relacorilant), the company expects future quarters to reflect sales from more than one medication, expanding its commercial footprint. In March 2026, the FDA approved Corcept’s selective glucocorticoid receptor antagonist, Lifyorli (relacorilant), in combination with nab-paclitaxel for the treatment of adult patients with platinum-resistant ovarian cancer. Management noted that in April 2026, Lifyorli, in combination with nab-paclitaxel, was added to NCCN Guidelines as a preferred regimen, with early uptake described as vigorous. Research and development expenses increased 9.1% year over year to $66.3 million in the first quarter of 2026, reflecting continued investment across oncology and other pipeline programs. Meanwhile, selling, general and administrative expenses surged 60.3% year over year to $145.4 million, reflecting higher spending to support the launch of Lifyorli. Corcept ended March 31, 2026, with cash and investments of $515.4 million, down from $532.4 million as of Dec 31, 2025. CORT raised its full-year 2026 revenue guidance to $950 million-$1.05 billion, signaling increased confidence as it transitions to a multi-product company. Previously, the company expected total revenues in the range of $900 million to $1 billion in 2026. The Zacks Consensus Estimate for revenues is pe...

Revenue growth was partially offset by seasonal insurance reauthorization hurdles and a temporary prior authorization backlog resulting from a specialty pharmacy vendor transition. Management attributes record new patient starts in March and April to increasing physician awareness following the publication of CATALYST and MOMENTUM trial data. The endocrinology business is being repositioned to address hypercortisolism as a common underlying cause of resistant diabetes and hypertension rather than a rare niche. Lifyorli's early FDA approval in platinum-resistant ovarian cancer followed clinical data showing a 35% reduction in risk of death, and the drug was included in NCCN guidelines as a preferred regimen 15 days after approval. The commercial strategy for Lifyorli focuses on its 'all-comer' label, which eliminates the need for biomarker testing and broadens the addressable patient population compared to competitors. Operational scaling is underway to support the long-term goal of reaching $2 billion in annual Cushing's revenue and $1 billion in U.S. oncology revenue by 2030. Revenue guidance for 2026 was increased to $950 million – $1.05 billion, driven primarily by the growth of the endocrinology business in Cushing's syndrome, with Lifyorli commercialization in oncology representing an early-stage contribution. Management expects to provide a regulatory update on the relacorilant NDA for Cushing's syndrome in the near future following recent FDA discussions. A Phase III trial for dazucorilant in ALS is planned for late 2024, focusing on preventing early death rather than functional decline based on 2-year survival data. The oncology portfolio is expected to expand significantly, with results for relacorilant combinations in various solid tumors due by the end of 2027. Phase IIb MONARCH trial results for miricorilant in MASH are anticipated by year-end, which will determine the transition to Phase III development. The shift to a net loss of $31.8 million reflects significant pre-launch commercial investments and ongoing R&D expansion across multiple therapeutic areas. A transition to a new specialty pharmacy vendor created a temporary administrative backlog that management is currently 'grinding through' to realize deferred revenue. The company is conducting a dose titration study for dazucorilant to address gastrointestinal tolerability issues that led t...

This article first appeared on GuruFocus. Revenue: $164.9 million in Q1 2026, up from $157.2 million in the prior year period. 2026 Revenue Guidance: Increased to $950 million to $1.05 billion. Net Loss: $31.8 million in Q1 2026, compared to net income of $20.5 million in Q1 2025. Cash and Investments: $515 million as of March 31, 2026. New Prescriptions: Record number of new prescriptions and prescribers in Q1 2026. LIFYORLI Approval: FDA approved for platinum-resistant ovarian cancer, with a 35% reduction in risk of death in pivotal trial. DAZALS Trial: 84% reduction in risk of death at one year for ALS patients, with a p-value of 0.0009. Warning! GuruFocus has detected 5 Warning Signs with CORT. Is CORT fairly valued? Test your thesis with our free DCF calculator. Release Date: April 30, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Corcept Therapeutics Inc (NASDAQ:CORT) reported a revenue increase to $164.9 million in Q1 2026, up from $157.2 million in the same period last year. The company has raised its 2026 revenue guidance to a range of $950 million to $1.05 billion. The FDA approved LIFYORLI for the treatment of platinum-resistant ovarian cancer, three-and-a-half months ahead of its PDUFA date. The CATALYST and MOMENTUM trials have shown promising results, indicating that hypercortisolism is a significant factor in resistant diabetes and hypertension. Corcept Therapeutics Inc (NASDAQ:CORT) expects its Cushing's syndrome business to grow to at least $2 billion in annual revenue by the end of the decade. Corcept Therapeutics Inc (NASDAQ:CORT) reported a net loss of $31.8 million in Q1 2026, compared to a net income of $20.5 million in the same period last year. Revenue was impacted by insurance reauthorization procedures that interrupted patient coverage, leading to a temporary dip. The transition to a new specialty pharmacy vendor caused a backlog in insurance prior-authorization, affecting revenue. The company faces challenges in scaling its pharmacy network to handle increasing prescription volumes. There are ongoing uncertainties and risks associated with forward-looking statements, as highlighted in their financial reports. Q: With the updated guidance, should we assume that it's mostly relacorilant contribution? Have any assumptions changed on Korlym? Can you help us just go through tha...

REDWOOD CITY, Calif. (AP) — REDWOOD CITY, Calif. (AP) — Corcept Therapeutics Inc. (CORT) on Thursday reported a loss of $31.2 million in its first quarter. The Redwood City, California-based company said it had a loss of 30 cents per share. The results met Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was also for a loss of 30 cents per share. The drug developer posted revenue of $164.9 million in the period, which did not meet Street forecasts. Three analysts surveyed by Zacks expected $172.4 million. Corcept expects full-year revenue in the range of $950 million to $1.05 billion. _____ This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on CORT at https://www.zacks.com/ap/CORT

Biopharma company Corcept Therapeutics (NASDAQ:CORT) will be announcing earnings results this Thursday after market hours. Here’s what to look for. Corcept missed analysts’ revenue expectations last quarter, reporting revenues of $202.1 million, up 11.1% year on year. It was a disappointing quarter for the company, with a significant miss of analysts’ revenue estimates and a significant miss of analysts’ EPS estimates. Is Corcept a buy or sell going into earnings? Read our full analysis here, it’s free for active Edge members. This quarter, the market is expecting Corcept’s revenue to grow 18.3% year on year, improving from the 7.1% increase it recorded in the same quarter last year. Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Corcept has missed Wall Street’s revenue estimates multiple times over the last two years. With Corcept being the first among its peers to report earnings this season, we don’t have anywhere else to look to get a hint at how this quarter will unravel for pharmaceuticals stocks. However, there has been positive investor sentiment in the segment, with share prices up 10.8% on average over the last month. Corcept is up 24.9% during the same time . ONE MORE THING: 3 Hidden Platforms Growing 3X Faster than Amazon, Google, and PayPal. Amazon, Google, and Meta all followed the same playbook: Dominate an ignored market. Build an unbeatable moat. Scale until you’re unstoppable. These three platforms are running that exact playbook right now. The early investors in Amazon made fortunes. The early investors in these could do the same. Get All 3 Stocks Here for FREE.